CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  Cancers of the genitourinary system affect hundreds of thousands of individuals in the United States each year and account for almost 30% of all newly diagnosed human cancer cases. Although genitourinary cancers are a diverse array of distinct diseases, tumors of the prostate are definitively the most prevalent and thus the topic of extensive ongoing clinical research. Consequently, the clinical management of prostate cancer is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care. To provide oncology nurses with therapeutic strategies to address the disparate needs of patients with metastatic prostate cancer, the Oncology Nursing Update audio series employs one-on-one interviews with medical oncologists and nurses who are experts in caring for patients with prostate cancer. On completion of this CNE activity, oncology nurses should be able to formulate an up-to-date and more complete approach to the care of these patients.
  
  PURPOSE STATEMENT
  To present the most current research developments in metastatic prostate cancer and to provide the perspectives of a nurse practitioner and clinical investigator on the treatment of metastatic prostate cancer.
  
  LEARNING OBJECTIVES

  • Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of castration-resistant prostate cancer (CRPC), including “secondary” hormonal agents, chemotherapy and radiopharmaceuticals.
  • Develop a plan of care to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
  • Review the available efficacy and safety data related to the use of the newly FDA-approved alpha emitter radium-223 and other bone-targeted agents in patients with skeletal metastases to facilitate appropriate counseling for individuals considering these therapeutic approaches.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with metastatic CRPC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  This is an audio CNE program. Participants should listen to the audio MP3s.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — Ms Sinibaldi had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Sartor — Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bayer HealthCare Pharmaceuticals, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Sanofi.
  
  EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Algeta US/Bayer HealthCare Pharmaceuticals and Astellas/Medivation Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: March 2014
  Expiration date: March 2015
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.